Looking for new anabolic treatment from rare diseases of bone formation

in Journal of Endocrinology
View More View Less
  • 1 M Rossi, Bone Physiopathology Unit, Genetics and Rare Diseases Research Area, Ospedale Pediatrico Bambino Gesù, Roma, Italy
  • 2 G Battafarano, Bone Physiopathology Unit, Genetics and Rare Diseases Research Area, Ospedale Pediatrico Bambino Gesù, Roma, Italy
  • 3 V De Martino, Department of Clinical, Internal, Anaesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Roma, Italy
  • 4 A Scillitani, Unit of Endocrinology and Diabetology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
  • 5 S Minisola, Department of Clinical, Internal, Anaesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Roma, Italy
  • 6 A Del Fattore, Bone Physiopathology Unit, Genetics and Rare Diseases Research Area, Ospedale Pediatrico Bambino Gesù, Roma, Italy

Correspondence: Andrea Del Fattore, Email: andrea.delfattore@opbg.net

Bone remodelling is a complex mechanism regulated by osteoclasts and osteoblasts and perturbation of this process leads to the onset of diseases, which may be characterized by altered bone erosion or formation. In this review we will describe some bone formation-related disorders as Sclerosteosis, Van Buchem disease, Hypophosphatasia and Camurati-Engelmann disease. In the past decades the research focused on these rare disorders offered the opportunity to understand important pathways regulating bone formation. Thus, the identification of the molecular defects behind the etiopathology of these diseases will open the way for new therapeutic approaches applicable also to the management of more common bone diseases including osteoporosis.

 

Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 511 511 99
Full Text Views 0 0 0
PDF Downloads 0 0 0